8-K: Applied Therapeutics Announces Fourth Quarter and Year-End 2024 Financial Results, Appoints Key Executives

Applied Therapeutics reports its Q4 and year-end 2024 financial results, highlighting key executive appointments and ongoing development program reviews.

Summary

• Applied Therapeutics reported its financial results for the fourth quarter and full year ended December 31, 2024.
• The company is focused on potential regulatory interactions for govorestat in Classic Galactosemia and SORD Deficiency.
• Key senior appointments were made across regulatory, medical, and quality affairs functions.
• John H. Johnson was appointed as Executive Chairman in December 2024.
• Les Funtleyder, the Chief Financial Officer, was appointed as Interim Chief Executive Officer.
• Todd F. Baumgartner, MD, MPH, was appointed as Chief Regulatory Officer in March 2025.
• Reena Thomas Colacot was appointed as Vice President and Head of Quality in January 2025.
• The company received a Complete Response Letter (CRL) from the FDA for the New Drug Application (NDA) for govorestat in Classic Galactosemia and is evaluating its response.
• The company is working with the FDA on the data needed to support an appropriate regulatory pathway for govorestat in SORD Deficiency, including the potential use of the accelerated approval pathway.
• Cash and cash equivalents totaled $79.4 million as of December 31, 2024, compared with $49.9 million at December 31, 2023.
• Research and development expenses for the year ended December 31, 2024, were $48.7 million, compared to $53.9 million for the year ended December 31, 2023.
• General and administrative expenses were $56.0 million for the year ended December 31, 2024, compared to $20.6 million for the year ended December 31, 2023.
• Net loss for the year ended December 31, 2024, was $105.6 million, or $0.76 per basic and diluted common share, compared to a net loss of $119.8 million, or $1.42 per basic and diluted common share, for the year ended December 31, 2023.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company has made key executive appointments and has a solid cash position, the Complete Response Letter from the FDA is a significant setback. The decrease in net loss is a positive sign, but the increase in general and administrative expenses is a concern.

Positives

• Cash and cash equivalents increased to $79.4 million as of December 31, 2024, compared to $49.9 million at the end of 2023.
• The net loss decreased to $105.6 million for the year ended December 31, 2024, compared to $119.8 million for the year ended December 31, 2023.
• Key senior appointments were made to bolster capabilities in regulatory, medical, and quality affairs.

Negatives

• The company received a Complete Response Letter (CRL) from the FDA for the New Drug Application (NDA) for govorestat in Classic Galactosemia.
• General and administrative expenses increased significantly to $56.0 million for the year ended December 31, 2024, compared to $20.6 million for the year ended December 31, 2023.
• The company experienced a net loss of $105.6 million for the year ended December 31, 2024.

Risks

• The company faces uncertainty regarding the FDA's approval of govorestat for Classic Galactosemia following the Complete Response Letter.
• The company's future financial performance depends on its ability to successfully develop and commercialize its product candidates.
• The company's increased general and administrative expenses could impact its profitability.
• The company's forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company remains focused on preparing for potential regulatory interactions regarding govorestat in both Classic Galactosemia and SORD Deficiency and optimizing its strategy for late-stage programs.

Management Comments

• We remain focused on preparing for potential regulatory interactions regarding govorestat in both Classic Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, said Les Funtleyder, Interim CEO and CFO of Applied Therapeutics.
• As we continue to optimize our strategy for our late-stage programs, we have also made key senior appointments across regulatory, medical and quality affairs functions to bolster our capabilities.
• We are confident in the promise of govorestat across indications and remain committed to our mission of addressing the unmet needs of patients with rare diseases.

Industry Context

Applied Therapeutics is operating in the competitive biopharmaceutical industry, focusing on rare diseases. The company's progress with govorestat and its interactions with the FDA are critical for its future success. Executive appointments suggest a strategic focus on regulatory and quality affairs.

Comparison to Industry Standards

• Applied Therapeutics' focus on rare diseases aligns with a growing trend in the biopharmaceutical industry, where companies are targeting niche markets with high unmet medical needs.
• The company's cash position of $79.4 million is relatively modest compared to larger pharmaceutical companies, but it is sufficient to fund its ongoing clinical trials and regulatory activities.
• The increase in general and administrative expenses is a concern, as it could indicate inefficiencies or excessive spending.
• The company's net loss per share of $0.76 is comparable to other clinical-stage biopharmaceutical companies that are investing heavily in research and development.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the Complete Response Letter from the FDA and the increase in general and administrative expenses.
• Employees may be affected by the changes in management and the company's strategic direction.
• Patients with Classic Galactosemia and SORD Deficiency are awaiting the potential approval of govorestat.
• The company's suppliers and creditors may be impacted by its financial performance.

Next Steps

• The company will continue to evaluate its response to the CRL from the FDA regarding govorestat for Classic Galactosemia.
• The company will continue to work with the FDA on the data needed to support an appropriate regulatory pathway for govorestat in SORD Deficiency.
• The company will focus on preparing for potential regulatory interactions regarding govorestat.

Key Dates

Keywords

Applied Therapeutics, Govorestat, Financial Results, Executive Appointments, Classic Galactosemia, SORD Deficiency, FDA, CRL, Biopharmaceutical, Rare Diseases